Korro Bio, Inc.

KRRO Nasdaq SEC CIK 1703647
Follow Korro Bio Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$18.9M +26.6% vs same quarter last year
EPS, diluted −$1.07 +60.9% vs same quarter last year
Operating cash flow −$17M +11.6% vs same quarter last year
Revenue by quarter
$0
$2.3M
$2.6M
$1.5M
$1.1M
$1.3M
$0
$0
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$6.4M−$117.3M
FY24$2.3M−$83.6M
FY23$0−$81.2M
FY22$0−$58M
FY21$14.1M−$84.7M
FY20$37M−$26.5M
FY19$28.9M−$18.7M
FY18-−$19.2M
FY17-−$20.2M
FY16--
MarginsShare of revenue
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−1906.4%−1834.5%
FY24−4047.1%−3680.4%
FY23--
FY22--
FY21−597.3%−602%
FY20−74.5%−71.7%
FY19−71.4%−64.8%
FY18--
FY17--
FY16--
Free cash flowOperating cash flow minus capital expenditure
−$100M−$50M$0$50MFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$79.1M
FY24−$78M
FY23−$75.1M
FY22−$58.8M
FY21−$79M
FY20−$51.9M
FY19$33.2M
FY18−$17.5M
FY17−$16.5M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Korro Bio
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY17FY19FY21FY23FY25
Show the numbers
YearKorro BioHealthcare median
FY25−1834.5%−40.6%
FY24−3680.4%−60.7%
FY23-−97.1%
FY22-−128.5%
FY21−602%−129.2%
FY20−71.7%−136.5%
FY19−64.8%−133.7%
FY18-−173.4%
FY17-−176.7%
FY16-−164.8%

News

No stories filed under Korro Bio yet - coverage appears here as the news feed clusters it.